WVE was heavily sold off after clinical trial data on WVE-007 was misinterpreted by the market—the study used healthy patients rather than obese patients, and the drug actually shows strong potential as a non-GLP-1 obesity treatment. Key catalysts include positive late-June clinical data (75-85% success probability), acquisition potential at $20-22.50/share, and strong cash runway through Q3 2028, suggesting significant upside if the market re-rates the stock.

Wave Life Sciences (WVE) fell 50% after misunderstood clinical trial data on obesity drug WVE-007 tested on healthy rather than obese patients; author believes data is actually positive and catalyst-driven reversal is likely in late June, with additional upside from acquisition speculation and mispriced call options that don't reflect 75-85% probability of positive trial outcomes.